2种含苦参素治疗方案治疗HBeAg阳性慢性乙型肝炎的成本-效果分析

Cost-effectiveness Analysis of 2 Therapeutic Schemes for HBeAg Positive Chronic Hepatitis B

目的:评价2种含苦参素治疗方案治疗HBeAg阳性慢性乙型肝炎(CHB)的经济学效果。方法:将83例患者随机分为2组,分别给予拉米夫定+苦参素(A组,40例)、干扰素α-2b+苦参素(B组,43例)治疗,总疗程均为12个月。以药品费和给药费为治疗成本,以HBV-DNA阴转率、HBeAg阴转率和丙氨酸氨基转移酶(ALT)复常率3项指标为临床疗效指标,进行成本-效果分析。结果:A、B组均有较好的临床疗效,3项指标组间比较差异均无统计学意义(P>0.05),但与B组3项指标的成本-效果比(333.3、345.2、256.5)比较,A组更低(220.8、276.0、200.73),以A组为参照的增量成本-效果比为-1289.9、906.4、818.0。结论:A组方案较B组方案治疗HBeAg阳性CHB疗效相似,但经济性较好。

OBJECTIVE：To evaluate the cost-effectiveness of 2 therapeutic schemes for HBeAg-positive chronic hepatitis B（CHB）.METHODS：83 patients with HBeAg-positive CHB were divided into 2 groups randomly：40 patients in group A received lamivudine and kurorinone;43 patients in group B received IFNα-2b and kurorinone.The course of treatment for the 2 groups all lasted for 12 months.Total treatment cost of the 2 groups was evaluated by drug cost and treatment cost.The cost-effectiveness of 2 groups was evaluated by the negative rate of HBV-DNA and HBeAg,and the normalization rate of ALT.RESULTS：The 2 groups had a better clinical therapeutic effect,and above three indexes had no significant difference in 2 groups（P0.05）.But the cost-effectiveness ratios of above three indexes in group B（333.3,345.2,256.5） were lower than those of group A（220.8,276.0,200.73）.Referred to group A,the incremental cost effectiveness ratios were-1289.9,906.4,818.0.CONCLUSION：Therapeutic efficacy of therapeutic schemes of group A is similar to that of group B in the treatment of HBeAg-positive CHB,but therapeutic schemes A is more economical than B.